Proactive: Turning risk into advantage: Racura Oncology’s push to make chemotherapy safer

Proactive Investors covered Racura Oncology’s cardio-oncology strategy and the potential of RC220 to make anthracycline-based chemotherapy safer for patients.

The article highlights progress in our international Phase 1 trial, our dual anticancer and cardioprotective approach, and recent IP advances supporting long-term value creation.

Read the full article here.